ImmunityBio, Inc. IBRX Total Current Liabilities
Total Current Liabilities at other companies
Other financials
Where this comes from
Reported directly by ImmunityBio, Inc. in its filing.
Tagged under the XBRL concept us-gaap:LiabilitiesCurrent.
The official record: ImmunityBio, Inc.’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about ImmunityBio, Inc.'s total current liabilities.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is ImmunityBio, Inc.'s total current liabilities?
- ImmunityBio, Inc. (IBRX) reported total current liabilities of $67.95M in Q1 2026.
- How has ImmunityBio, Inc.'s total current liabilities changed year-over-year?
- ImmunityBio, Inc.'s total current liabilities increased by 38.1% year-over-year, from $49.21M to $67.95M.
- What is the long-term trend for ImmunityBio, Inc.'s total current liabilities?
- Over 5 years (2020 to 2025), ImmunityBio, Inc.'s total current liabilities has grown at a -1.9% compound annual growth rate (CAGR), from $68.13M to $61.75M.
- What does total current liabilities mean?
- The total amount of debt and obligations due within one year.
- How do you interpret total current liabilities?
- Lower levels relative to current assets indicate stronger liquidity, while rising levels may signal potential cash flow pressure.
- How does total current liabilities compare across companies?
- A fundamental liquidity metric used across all sectors to assess short-term solvency.